|
Schwarz Pharma AG - Comparative Business Analysis Snapshot
Business Description
Schwarz Pharma AG. The Group's principal activity is to research, develop, manufacture and market pharmaceuticals. It involves in bulk manufacturing, packaging and material management of pharmaceutical drugs. It specializes in manufacturing solid oral dosage forms and packing with modern blister machines. It also provides raw material and packaging materials for pharmaceutical industries. The drugs are manufactured for the following concerns: Cardiovascular diseases, Gastro intestinal diseases, Urology and Central nervous system related diseases. It operates under the brand names Atmadisc, Deponit, Dycanil, Elantan, Firin, Harzol, Isoket, Naramig, Nipruss and Sita. The Group operates in Germany, Italy, the United Kingdom, the United States, Switzerland, China, Hong Kong and Philippines.
Competitor Analysis
This analysis compares Schwarz Pharma AG with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
